Cargando…
Perspectives on statistical strategies for the regulatory biomarker qualification process
Qualification of a biomarker for use in a medical product development program requires a statistical strategy that aligns available evidence with the proposed context of use (COU), identifies any data gaps to be filled and plans any additional research required to support the qualification. Accumula...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Medicine Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293027/ https://www.ncbi.nlm.nih.gov/pubmed/34037457 http://dx.doi.org/10.2217/bmm-2020-0523 |
_version_ | 1783724940206276608 |
---|---|
author | Hendrix, Suzanne B Mogg, Robin Wang, Sue Jane Chakravarty, Aloka Romero, Klaus Dickson, Samuel P Sauer, John-Michael McShane, Lisa M |
author_facet | Hendrix, Suzanne B Mogg, Robin Wang, Sue Jane Chakravarty, Aloka Romero, Klaus Dickson, Samuel P Sauer, John-Michael McShane, Lisa M |
author_sort | Hendrix, Suzanne B |
collection | PubMed |
description | Qualification of a biomarker for use in a medical product development program requires a statistical strategy that aligns available evidence with the proposed context of use (COU), identifies any data gaps to be filled and plans any additional research required to support the qualification. Accumulating, interpreting and analyzing available data is outlined, step-by-step, illustrated by a qualified enrichment biomarker example and a safety biomarker in the process of qualification. The detailed steps aid requestors seeking qualification of biomarkers, allowing them to organize the available evidence and identify potential gaps. This provides a statistical perspective for assessing evidence that parallels clinical considerations and is intended to guide the overall evaluation of evidentiary criteria to support a specific biomarker COU. |
format | Online Article Text |
id | pubmed-8293027 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Future Medicine Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-82930272021-07-22 Perspectives on statistical strategies for the regulatory biomarker qualification process Hendrix, Suzanne B Mogg, Robin Wang, Sue Jane Chakravarty, Aloka Romero, Klaus Dickson, Samuel P Sauer, John-Michael McShane, Lisa M Biomark Med Perspective Qualification of a biomarker for use in a medical product development program requires a statistical strategy that aligns available evidence with the proposed context of use (COU), identifies any data gaps to be filled and plans any additional research required to support the qualification. Accumulating, interpreting and analyzing available data is outlined, step-by-step, illustrated by a qualified enrichment biomarker example and a safety biomarker in the process of qualification. The detailed steps aid requestors seeking qualification of biomarkers, allowing them to organize the available evidence and identify potential gaps. This provides a statistical perspective for assessing evidence that parallels clinical considerations and is intended to guide the overall evaluation of evidentiary criteria to support a specific biomarker COU. Future Medicine Ltd 2021-05-26 2021-06 /pmc/articles/PMC8293027/ /pubmed/34037457 http://dx.doi.org/10.2217/bmm-2020-0523 Text en © 2021 Pentara Corporation https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | Perspective Hendrix, Suzanne B Mogg, Robin Wang, Sue Jane Chakravarty, Aloka Romero, Klaus Dickson, Samuel P Sauer, John-Michael McShane, Lisa M Perspectives on statistical strategies for the regulatory biomarker qualification process |
title | Perspectives on statistical strategies for the regulatory biomarker qualification process |
title_full | Perspectives on statistical strategies for the regulatory biomarker qualification process |
title_fullStr | Perspectives on statistical strategies for the regulatory biomarker qualification process |
title_full_unstemmed | Perspectives on statistical strategies for the regulatory biomarker qualification process |
title_short | Perspectives on statistical strategies for the regulatory biomarker qualification process |
title_sort | perspectives on statistical strategies for the regulatory biomarker qualification process |
topic | Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293027/ https://www.ncbi.nlm.nih.gov/pubmed/34037457 http://dx.doi.org/10.2217/bmm-2020-0523 |
work_keys_str_mv | AT hendrixsuzanneb perspectivesonstatisticalstrategiesfortheregulatorybiomarkerqualificationprocess AT moggrobin perspectivesonstatisticalstrategiesfortheregulatorybiomarkerqualificationprocess AT wangsuejane perspectivesonstatisticalstrategiesfortheregulatorybiomarkerqualificationprocess AT chakravartyaloka perspectivesonstatisticalstrategiesfortheregulatorybiomarkerqualificationprocess AT romeroklaus perspectivesonstatisticalstrategiesfortheregulatorybiomarkerqualificationprocess AT dicksonsamuelp perspectivesonstatisticalstrategiesfortheregulatorybiomarkerqualificationprocess AT sauerjohnmichael perspectivesonstatisticalstrategiesfortheregulatorybiomarkerqualificationprocess AT mcshanelisam perspectivesonstatisticalstrategiesfortheregulatorybiomarkerqualificationprocess |